{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Sangamo Therapeutics, Inc.
Is Sangamo Therapeutics, Inc. technically bullish or bearish?
As of May 19, 2025, the market trend is mildly bearish, influenced by bearish weekly MACD and Bollinger Bands, while monthly indicators show mixed signals, suggesting caution.
Who are in the management team of Sangamo Therapeutics, Inc.?
As of March 2022, the management team of Sangamo Therapeutics, Inc. includes Dr. Alexander Macrae as President and CEO, with Dr. Kenneth Hillan and several independent directors: Mr. Robert Carey, Dr. John Markels, Mr. James Meyers, and Ms. H. Stewart Parker.
What does Sangamo Therapeutics, Inc. do?
Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genomic therapies. As of March 2025, it reported net sales of $6 million and a net loss of $31 million, with a market cap of $118.55 million.
How big is Sangamo Therapeutics, Inc.?
As of Jun 18, Sangamo Therapeutics, Inc. has a market capitalization of 118.55 million, with net sales of 63.76 million and a net profit of -80.75 million over the last four quarters. The company's shareholder's funds are 22.77 million, and total assets are 105.31 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
